All Stories

  1. Individual prevention and containment measures in schools in Catalonia, Spain, and community transmission of SARS-CoV-2 after school re-opening
  2. Socio-anthropological methods to study the feasibility and acceptability of the minimally invasive autopsy from the perspective of local communities: lessons learnt from a large multi-centre study
  3. Efficacy and Tolerability Outcomes of a Phase II, Randomized, Open-Label, Multicenter Study of a New Water-Dispersible Pediatric Formulation of Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Plasmodium falciparum Malaria in African I...
  4. Respiratory microbiota and lower respiratory tract disease
  5. The performance of the expanded programme on immunization in a rural area of Mozambique
  6. A comparison of human metapneumovirus and respiratory syncytial virus WHO-defined severe pneumonia in Moroccan children
  7. Pathological Methods Applied to the Investigation of Causes of Death in Developing Countries: Minimally Invasive Autopsy Approach
  8. Knowledge gaps on paediatric respiratory infections in Morocco, Northern Africa
  9. Establishment of the Ivermectin Research for Malaria Elimination Network: updating the research agenda
  10. Global epidemiology of yaws: a systematic review
  11. Diagnóstico y tratamiento de la malaria importada en España: recomendaciones del Grupo de Trabajo de Malaria de la Sociedad Española de Medicina Tropical y Salud Internacional (SEMTSI)
  12. Tailoring a Pediatric Formulation of Artemether-Lumefantrine for Treatment of Plasmodium falciparum Malaria
  13. Diarrheal Disease in Rural Mozambique: Burden, Risk Factors and Etiology of Diarrheal Disease among Children Aged 0–59 Months Seeking Care at Health Facilities
  14. Characterization of Plasmodium vivax-associated admissions to reference hospitals in Brazil and India
  15. Mass Treatment with Single-Dose Azithromycin for Yaws
  16. Malaria-associated hypoglycaemia in children
  17. Risk factors for a poor outcome among children admitted with clinically severe pneumonia to a university hospital in Rabat, Morocco
  18. Biomarker discovery for childhood infections: paving the way for a diagnostic revolution in the developing world
  19. The Importance of Being vivax
  20. Development of a pediatric formulation for treatment of P. falciparum malaria: Coartem® (artemether-lumefantrine) Dispersible
  21. G6PD deficiency in Latin America: systematic review on prevalence and variants
  22. Influence of age on the haemoglobin concentration of malaria-infected patients in a reference centre in the Brazilian Amazon
  23. Getting ready for malaria elimination: a check list of critical issues to consider
  24. Sensitivity and specificity of a rapid point-of-care test for active yaws: a comparative study
  25. Paediatric Pharmacovigilance: Use of Pharmacovigilance Data Mining Algorithms for Signal Detection in a Safety Dataset of a Paediatric Clinical Study Conducted in Seven African Countries
  26. Haemophilus ducreyi as a cause of skin ulcers in children from a yaws-endemic area of Papua New Guinea: a prospective cohort study
  27. Impact of age of first exposure to Plasmodium falciparum on antibody responses to malaria in children: a randomized, controlled trial in Mozambique
  28. Clinical complications of G6PD deficiency in Latin American and Caribbean populations: systematic review and implications for malaria elimination programmes
  29. Epidemiology, etiology, x-ray features, importance of co-infections and clinical features of viral pneumonia in developing countries
  30. In vivo efficacy of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated falciparum malaria in children: a multisite, open-label, two-cohort, clinical trial in Mozambique
  31. Correction: Advances in the Diagnosis of Endemic Treponematoses: Yaws, Bejel, and Pinta
  32. Advances in the Diagnosis of Endemic Treponematoses: Yaws, Bejel, and Pinta
  33. Detection of Streptococcus pneumoniae and Haemophilus influenzae Type B by Real-Time PCR from Dried Blood Spot Samples among Children with Pneumonia: A Useful Approach for Developing Countries
  34. Developments in therapy and diagnosis of yaws and future prospects
  35. Antibiotic Usage Prior and During Hospitalization for Clinical Severe Pneumonia in Children under Five Years of Age in Rabat, Morocco
  36. Development of a post-mortem procedure to reduce the uncertainty regarding causes of death in developing countries
  37. Lower Respiratory Tract Infections Associated with Rhinovirus during Infancy and Increased Risk of Wheezing during Childhood. A Cohort Study
  38. Ivermectin to reduce malaria transmission: a research agenda for a promising new tool for elimination
  39. Severe malnutrition among children under the age of 5 years admitted to a rural district hospital in southern Mozambique
  40. Malaria epidemiology in Lihir Island, Papua New Guinea
  41. Intermittent preventive treatment of malaria in pregnant women and infants: making best use of the available evidence
  42. Low antibodies against Plasmodium falciparum and imbalanced pro-inflammatory cytokines are associated with severe malaria in Mozambican children: a case–control study
  43. Glucose-6-phosphate dehydrogenase deficiency, chlorproguanil-dapsone with artesunate and post-treatment haemolysis in African children treated for uncomplicated malaria
  44. Risk Factors and Characterization of Plasmodium Vivax-Associated Admissions to Pediatric Intensive Care Units in the Brazilian Amazon
  45. APPROACHING THE TARGET: THE PATH TOWARDS AN EFFECTIVE MALARIA VACCINE
  46. The Role of Age and Exposure to Plasmodium falciparum in the Rate of Acquisition of Naturally Acquired Immunity: A Randomized Controlled Trial
  47. Single-dose azithromycin versus benzathine benzylpenicillin for treatment of yaws in children in Papua New Guinea: an open-label, non-inferiority, randomised trial
  48. Plasmodium vivax malaria in Mali: a study from three different regions
  49. Integrated vector management targeting Anopheles darlingi populations decreases malaria incidence in an unstable transmission area, in the rural Brazilian Amazon
  50. The Use of Artemether-Lumefantrine for the Treatment of Uncomplicated Plasmodium vivax Malaria
  51. Similar efficacy and safety of artemether-lumefantrine (Coartem®) in African infants and children with uncomplicated falciparum malaria across different body weight ranges
  52. Antimalarial efficacy of piperaquine-based antimalarial combination therapies: facts and uncertainties
  53. Erythropoietin Levels Are Not Independently Associated with Malaria-Attributable Severe Disease in Mozambican Children
  54. The Impact of a Filariasis Control Program on Lihir Island, Papua New Guinea
  55. Four year immunogenicity of the RTS,S/AS02A malaria vaccine in Mozambican children during a phase IIb trial
  56. Inherent illnesses and attacks: an ethnographic study of interpretations of childhood Acute Respiratory Infections (ARIs) in Manhiça, southern Mozambique
  57. Epidemiology, Molecular Characterization and Antibiotic Resistance of Neisseria meningitidis from Patients ≤15 Years in Manhiça, Rural Mozambique
  58. Outcome Predictors in Treatment of Yaws
  59. Outcome Predictors in Treatment of Yaws
  60. Estado actual de la malaria (I): diagnóstico y tratamiento
  61. Estado actual de la malaria (y II): obstáculos hacia la eliminación y desafíos desde el punto de vista de la investigación
  62. Association of Severe Malaria Outcomes with Platelet-Mediated Clumping and Adhesion to a Novel Host Receptor
  63. Defying malaria: Fathoming severe Plasmodium vivax disease
  64. Etiology and Epidemiology of Viral Pneumonia Among Hospitalized Children in Rural Mozambique
  65. Safety, Immunogenicity and Duration of Protection of the RTS,S/AS02D Malaria Vaccine: One Year Follow-Up of a Randomized Controlled Phase I/IIb Trial
  66. Procalcitonin and C-Reactive Protein for Invasive Bacterial Pneumonia Diagnosis among Children in Mozambique, a Malaria-Endemic Area
  67. Dihydroartemisinin-Piperaquine and Artemether-Lumefantrine for Treating Uncomplicated Malaria in African Children: A Randomised, Non-Inferiority Trial
  68. Drug Resistance in Malaria in Developing Countries
  69. Long‐Term Safety and Efficacy of the RTS,S/AS02A Malaria Vaccine in Mozambican Children
  70. Severe malaria and concomitant bacteraemia in children admitted to a rural Mozambican hospital
  71. Insights into Long-Lasting Protection Induced by RTS,S/AS02A Malaria Vaccine: Further Results from a Phase IIb Trial in Mozambican Children
  72. A 10 year study of the cause of death in children under 15 years in Manhiça, Mozambique
  73. Community-Acquired Bacteremia Among Children Admitted to a Rural Hospital in Mozambique
  74. Efficacy and safety of artemether-lumefantrine dispersible tablets compared with crushed commercial tablets in African infants and children with uncomplicated malaria: a randomised, single-blind, multicentre trial
  75. Malaria in rural Mozambique. Part I: Children attending the outpatient clinic
  76. Safety of the RTS,S/AS02A malaria vaccine in Mozambican children during a Phase IIb trial
  77. Malaria in rural Mozambique. Part II: children admitted to hospital
  78. Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial
  79. Towards an effective malaria vaccine
  80. Vacunaciones en un hospital rural de Mozambique
  81. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial
  82. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial